Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs
We assessed the effect of extending the range of cardiovascular (CV) end points to include hospitalization for unstable angina and hospitalization for coronary revascularization (Extended Major Adverse Cardiac Event criteria (MACE)) in addition to the standard ones, namely, CV-related death, nonfata...
Saved in:
Published in | Clinical pharmacology and therapeutics Vol. 91; no. 3; p. 514 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.03.2012
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Be the first to leave a comment!